With ongoing improvements in clinical trials and the development of predictive biomarkers, the potential of HER3 targeting in NSCLC shines brightly, fostering renewed optimism for surmounting EGFR TKI resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.